272 related articles for article (PubMed ID: 28212559)
21. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
22. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
23. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
[TBL] [Abstract][Full Text] [Related]
24. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
[TBL] [Abstract][Full Text] [Related]
25. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Gao H; Jiang Q; Han Y; Peng J; Wang C
Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
[TBL] [Abstract][Full Text] [Related]
26. Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
Zhang X; Zhang X; Huang T; Geng J; Liu M; Zheng J
Int J Clin Exp Pathol; 2015; 8(3):2823-8. PubMed ID: 26045790
[TBL] [Abstract][Full Text] [Related]
27. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
[TBL] [Abstract][Full Text] [Related]
28. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
29. Eupafolin enhances TRAIL-mediated apoptosis through cathepsin S-induced down-regulation of Mcl-1 expression and AMPK-mediated Bim up-regulation in renal carcinoma Caki cells.
Han MA; Min KJ; Woo SM; Seo BR; Kwon TK
Oncotarget; 2016 Oct; 7(40):65707-65720. PubMed ID: 27582546
[TBL] [Abstract][Full Text] [Related]
30. VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma.
Sinha S; Cao Y; Dutta S; Wang E; Mukhopadhyay D
J Cell Mol Med; 2010 Mar; 14(3):647-58. PubMed ID: 19017359
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
32. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
[TBL] [Abstract][Full Text] [Related]
33. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
Kitano H; Kitadai Y; Teishima J; Yuge R; Shinmei S; Goto K; Inoue S; Hayashi T; Sentani K; Yasui W; Matsubara A
Cancer Med; 2017 Oct; 6(10):2308-2320. PubMed ID: 28834289
[TBL] [Abstract][Full Text] [Related]
35. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy.
Chen D; Sun X; Zhang X; Cao J
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22195. PubMed ID: 30004155
[TBL] [Abstract][Full Text] [Related]
36. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
37. Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death.
Zheng W; Zhou CY; Zhu XQ; Wang XJ; Li ZY; Chen XC; Chen F; Che XY; Xie X
Biomed Pharmacother; 2018 Oct; 106():175-182. PubMed ID: 29958141
[TBL] [Abstract][Full Text] [Related]
38. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
39. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
